Related Experiment Video
Updated: Aug 14, 2026
09:05
Generation of Oligodendrocytes and Oligodendrocyte-Conditioned Medium for Co-Culture Experiments
Published on: February 9, 2020
Hypoglycemia influences oligodendrocyte development and myelin formation
1Department of Pediatrics, Yale Child Health Research Center, Section of Developmental Endocrinology and Biology, Yale University School of Medicine, New Haven, CT 06520, USA. scott.rivkees@yale.edu
Neuroreport
|December 20, 2005
Summary
Hypoglycemia, or low blood sugar, impairs oligodendrocyte development and myelination in the central nervous system. This condition also triggers programmed cell death in oligodendrocyte precursor cells.
Area of Science:
- Neuroscience
- Cell Biology
- Developmental Biology
Background:
- Central nervous system white matter damage is linked to hypoglycemia.
- Hypoglycemia may impact oligodendrocytes and myelin formation.
Purpose of the Study:
- To investigate the effects of hypoglycemia on oligodendrocyte development and myelination.
- To examine the impact of glucose levels on oligodendrocyte precursor cells and myelinated fiber formation.
Main Methods:
- Cultured oligodendrocyte precursor cells were studied under varying glucose concentrations.
- Cerebellar slice cultures were used to assess myelinated fiber formation.
- Apoptotic cell death and caspase-3 activation were analyzed.
Main Results:
- Decreasing glucose concentrations reduced oligodendrocyte precursor cell proliferation, maturation, and migration.
- Hypoglycemia induced apoptotic cell death and caspase-3 activation in these cells.
- Reduced glucose levels in slice cultures led to decreased myelinated fiber density.
Conclusions:
- Hypoglycemia inhibits oligodendrocyte development and the process of myelination.
- Hypoglycemia induces apoptosis in oligodendrocyte precursor cells, impacting myelin formation.
More Related Videos
Related Concept Videos
01:26Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
01:24Oligosaccharide Assembly
Protein glycosylation starts in the ER lumen and continues in the Golgi apparatus. Glycosyltransferases catalyze the addition of sugar molecules or glycosylation of proteins. Usually, these enzymes add sugars to the hydroxyl groups of selected serine or threonine residues to form O-linked glycans or the amino groups of asparagine residues to form N-linked glycans. Different positions on the same polypeptide chain can contain differently linked glycans.
Multiple sugar molecules that may or may...
Multiple sugar molecules that may or may...
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Insulin and C-peptide are co-secreted in...